Leukemia Clinical Trials in Marseille

34 recruitingMarseille, France

Showing 120 of 34 trials

Recruiting
Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 2

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Acute Myeloid Leukemia
Institut Paoli-Calmettes35 enrolled1 locationNCT06055621
Recruiting
Phase 2

De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

Acute Myeloid Leukemia
Institut Paoli-Calmettes50 enrolled1 locationNCT06557421
Recruiting
Phase 4

Asciminib Roll-over Study

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 3

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 1

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC100 enrolled9 locationsNCT06651229
Recruiting
Phase 3

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 2

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Acute Myeloid Leukemia in Remission
Nantes University Hospital302 enrolled23 locationsNCT05917405
Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled79 locationsNCT06137118
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC400 enrolled101 locationsNCT04811560
Recruiting
Phase 1Phase 2

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic Phase
Terns, Inc.180 enrolled54 locationsNCT06163430
Recruiting
Phase 3

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology160 enrolled112 locationsNCT05327894
Recruiting

Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL

Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
Nantes University Hospital60 enrolled14 locationsNCT07099443
Recruiting
Not Applicable

Evaluation of the Efficacy of a Virtual Reality When Placing a Needle on an Implantable Venous Access Device in Children With Leukemia

Acute LeukemiaVirtual RealityChildren and Adolescents+1 more
University Hospital, Clermont-Ferrand120 enrolled4 locationsNCT06697275
Recruiting

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)
Acute Leukemia French Association5,000 enrolled30 locationsNCT04777916
Recruiting
Phase 1Phase 2

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMyelodysplastic Syndrome/Acute Myeloid Leukemia
AB Science78 enrolled10 locationsNCT05211570
Recruiting
Phase 1Phase 2

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05745714
Recruiting
Phase 1Phase 2

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05751044
Recruiting
Phase 1Phase 2

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled36 locationsNCT05658640